STARS Webinar - Cancer Drug Development in the Era of Precision Medicine-Cancer Drug Development in the Era of Precision Medicine Slide Deck

Cancer Drug Development in the Era of Precision Medicine Slide Deck

Pdf Summary

This document discusses the development of cancer drugs in the era of precision medicine. It starts by explaining the traditional view of lung cancer and the effect of chemotherapy in advanced non-small cell lung cancer (NSCLC). The document then highlights the discovery of EGFR mutations associated with sensitivity to gefitinib and erlotinib in 2004, leading to the identification of genetic "drivers" of cancer. It also mentions the importance of understanding acquired resistance to overcome it.<br /><br />The value of routine lung tumor testing is discussed with the Iressa Pan-Asia Study (IPASS) in 2009. The document further explores the impact of targeted therapies in lung cancer and how biomarker testing can guide therapy. It mentions the unprecedented survival in some melanoma patients on immunotherapy and the improvement in overall survival in NSCLC with checkpoint inhibitor therapy.<br /><br />There is ongoing research in extensive-stage small cell lung cancer (SCLC) regarding the use of checkpoint inhibitor therapy. The document also highlights the multiple options available today for molecularly defined subsets of NSCLC and the potential of liquid biopsies in enabling precision medicine.<br /><br />Real world data and synthetic controls are discussed as having an impact on access to certain drugs. The document concludes by noting the significance of scientific breakthroughs and new paradigms in improving outcomes in lung cancer, including histology-based diagnosis, molecular-based diagnosis and targeted therapy, and cancer immunotherapy. Finally, it mentions the need for further research to understand who benefits the most and the use of new approaches such as liquid biopsies and real-world data.

Keywords

precision medicine

lung cancer

chemotherapy

EGFR mutations

targeted therapies

biomarker testing

immunotherapy

checkpoint inhibitor therapy

liquid biopsies

real-world data